AllianceBernstein’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

AllianceBernstein’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-13,700	Closed	-$23K	–	3479
2022 Q1	$23K	Sell	13,700 -900	-6%	-$1.61K	﹤0.01%	3216
2021 Q4	$35K	Hold	14,600	–	–	﹤0.01%	3257
2021 Q3	$80K	Hold	14,600	–	–	﹤0.01%	3205
2021 Q2	$109K	Buy	14,600 +1,600	+12%	+$11.3K	﹤0.01%	3238
2021 Q1	$105K	Sell	13,000 -700	-5%	-$7.63K	﹤0.01%	3147
2020 Q4	$125K	Hold	13,700	–	–	﹤0.01%	3082
2020 Q3	$152K	Sell	13,700 -1,700	-11%	-$11.8K	﹤0.01%	3009
2020 Q2	$114K	Buy	+15,400	New	+$103K	﹤0.01%	3091

Other funds holding KLDO

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

AllianceBernstein's KLDO Position: Q2 2022 in Review

AllianceBernstein sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 13,700 shares — an estimated $23K sold.

AllianceBernstein first reported a position in KLDO in Q2 2020 and held it in 8 quarters. The position peaked at $152K in Q3 2020. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

AllianceBernstein reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
AllianceBernstein sold 13,700 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $23K.
AllianceBernstein first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
AllianceBernstein's Kaleido Biosciences, Inc. Common Stock position peaked at $152K in Q3 2020.
3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.